Kennewick, WA, United States

ADVANCED MEDICAL ISOTOPE

www.isotopeworld.com
Kennewick, WA, United States
SEARCH FILTERS
Time filter
Source Type

News Article | August 1, 2017
Site: www.accesswire.com

RICHLAND, WA / ACCESSWIRE / August 1, 2017 / Advanced Medical Isotope Corporation ("AMI") (OTC PINK: ADMD), a late stage radiation oncology focused medical device company, will host a shareholder update webcast today Tuesday, August 1, at 1:30 p.m. Eastern (10:30 a.m. Pacific). Dr. Michael K. Korenko, President and CEO of AMI will host the webcast and will provide an overview of AMI's business as well as an update on near-term milestone achievements. A live Q&A session will follow the presentation. Archived replay will be available following the webcast. The strategic market sector of Advanced Medical Isotope Corporation (ADMD) is isotope applications. Currently, the company is engaged in the development of RadioGel™, an Yttrium-90 based brachytherapy device, for the treatment of tumors. Brachytherapy uses radiation to destroy cancerous tumors by placing a radioactive isotope inside the treatment area. The company is engaging the FDA for permission to use RadioGel™ for the treatment of advanced basal and squamous skin cancers. The IsoPet Solutions division is focused on demonstrating the safety and therapeutic effectiveness for different animal cancers in four different university veterinary hospitals. After this demonstration phase the plan is to sell RadioGelTM to the private animal clinics. The Company currently is outsourcing material aspects of manufacturing of its product in the United States and intends to enter into licensing arrangements outside of the United States for the manufacturing and distribution of RadioGel™ in other countries. For more information, please visit our websites: www.isotopeworld.com and www.isopetsolutions.com. RadioGel™ is a hydrogel liquid containing tiny Yttrium-90 phosphate particles which may be injected into a tumor. This hydrogel liquid is maintained at a temperature below body temperature but begins to gel, harden, once it is injected into the body and as the temperature increases up to body temperature, thereby locking the particles in place. The particles emit a very high concentrated and contained beta irradiation to kill the tumor. The beta radiation has a short penetration distance so there is minimal collateral damage outside of the injected area. RadioGel™ also has a short half-life - after 10 days only about 5% of the radiation remains; as opposed to other available options that would 50% after 10 days. This is an outpatient treatment much safer to the personnel treating the patient than competing brands and the patient can go home immediately after with no risk to any family members. This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. You can identify these statements by the use of the words "may," "will," "should," "plans," "expects," "anticipates," "continue," "estimates," "projects," "intends," and similar expressions. Forward-looking statements involve risks and uncertainties that could cause results to differ materially from those projected or anticipated. These risks and uncertainties include, but are not limited to, the Company's ability to successfully execute its expanded business strategy, including by entering into definitive agreements with suppliers, commercial partners and customers; general economic and business conditions, effects of continued geopolitical unrest and regional conflicts, competition, changes in technology and methods of marketing, delays in completing various engineering and manufacturing programs, changes in customer order patterns, changes in product mix, continued success in technical advances and delivering technological innovations, shortages in components, production delays due to performance quality issues with outsourced components, regulatory requirements and the ability to meet them, government agency rules and changes, and various other factors beyond the Company's control.


News Article | July 11, 2017
Site: www.accesswire.com

RICHLAND, WA / ACCESSWIRE / July 11, 2017 / Advanced Medical Isotope Corporation ("AMI") (OTC PINK: ADMD), a late stage radiation oncology focused medical device company today announced that a new proprietary process has been developed that significantly improves originally licensed technology on the company's Y-90 RadioGel™ device. After five months of effort, the AMI team have finalized an improved manufacturing process for our yttrium phosphate particles. We conducted more than thirty process development runs to achieve the most cost-effective process to reproducibly give us the small particles that we desire. Small particles perfuse further into the tumor and reduce the number of injections required for dose coverage in large tumors. In parallel, we concentrated on reducing the time and cost required for manufacturing and increasing the batch yield. As an example, one production step was reduced from 20 hours to just an hour. Product yield increased from 80% to 99.99%. The process is elegantly simple, but based on fundamental understanding of the underlying chemistry involved. IsoTherapeutics, a key manufacturing and testing contractor, did a very professional job working with our team to explore all of the key manufacturing variables. AMI Interim CEO and President Dr. Mike Korenko stated, "This is a significant improvement over the technology that was originally licensed to AMI from the Pacific Northwest National Laboratory. This new proprietary process is an important part of our intellectual property and will reduce our manufacturing costs to position AMI to make a profit on future sales. The manufacturing process has now been institutionalized in a formal Standard Operating Procedure, which is needed to ensure a safe reproducible product for animal and human therapy and it is the protocol required by the Food and Drug Administration." Dr. Korenko added, "This accomplishment required a great deal of effort and is a major step in executing our business plan, which I outlined in my first letter to Shareholders January 2017." AMI previously created the Standard Operating Procedures for the hydrogel (RadioGel™). We are now working on the Quality Assurance and Quality Control Plans and to convert all process activities to GMP (Good Manufacturing Processes) which is a FDA requirement. This will complete the entire disciplined manufacturing process requirements. The strategic market sector of Advanced Medical Isotope Corporation (ADMD) is isotope applications. Currently, the company is engaged in the development of RadioGelTM, an Yttrium-90 based brachytherapy device, for the treatment of tumors. Brachytherapy uses radiation to destroy cancerous tumors by placing a radioactive isotope inside the treatment area. The company is engaging the FDA for permission to use RadioGel for the treatment of advanced basal and squamous skin cancers. The IsoPet Solutions division is focused on demonstrating the safety and therapeutic effectiveness for different animal cancers in four different university veterinary hospitals. After this demonstration phase the plan is to sell RadioGelTM to the private animal clinics. The Company currently is outsourcing material aspects of manufacturing of its product in the United States and intends to enter into licensing arrangements outside of the United States for the manufacturing and distribution of RadioGelTM in other countries. For more information, please visit our websites: www.isotopeworld.com and www.isopetsolutions.com. RadioGel™ is a hydrogel liquid containing tiny Yttrium-90 phosphate particles which may be injected into a tumor. This hydrogel liquid is maintained at a temperature below body temperature but begins to gel, harden, once it is injected into the body and as the temperature increases up to body temperature, thereby locking the particles in place. The particles emit a very high concentrated and contained beta irradiation to kill the tumor. The beta radiation has a short penetration distance so there is minimal collateral damage outside of the injected area. RadioGel™ also has a short half-life - after 10 days only about 5% of the radiation remains; as opposed to other available options that would 50% after 10 days. This is an outpatient treatment much safer to the personnel treating the patient than competing brands and the patient can go home immediately after with no risk to any family members. This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. You can identify these statements by the use of the words "may," "will," "should," "plans," "expects," "anticipates," "continue," "estimates," "projects," "intends," and similar expressions. Forward-looking statements involve risks and uncertainties that could cause results to differ materially from those projected or anticipated. These risks and uncertainties include, but are not limited to, the Company's ability to successfully execute its expanded business strategy, including by entering into definitive agreements with suppliers, commercial partners and customers; general economic and business conditions, effects of continued geopolitical unrest and regional conflicts, competition, changes in technology and methods of marketing, delays in completing various engineering and manufacturing programs, changes in customer order patterns, changes in product mix, continued success in technical advances and delivering technological innovations, shortages in components, production delays due to performance quality issues with outsourced components, regulatory requirements and the ability to meet them, government agency rules and changes, and various other factors beyond the Company's control.


The Company would like to welcome Robert G. Wolfangel as a new independent Board member. In addition, Dr. Michael K. Korenko, AMI's President, and CEO, was named to the Board of Directors and Dr. Carlton Cadwell was re-elected Chairman of the Board. Mr. James Katzaroff, AMI's former President, and CEO, agreed as part of his separation from the company to step down and not seek re-election to the Board of Directors. Thomas J. Clement did not stand for re-election this year. The company would like to thank both Tom and Jim for their past service. Following the shareholder meeting, the Company hosted a Shareholder Update Webcast and Q&A. The archived webcast link is available to be viewed at: The strategic market sector of Advanced Medical Isotope Corporation (ADMD) is isotope applications. Currently, the company is engaged in the development of RadioGel™, an Yttrium-90 based brachytherapy device, for the treatment of tumors. Brachytherapy uses radiation to destroy cancerous tumors by placing a radioactive isotope inside the treatment area. The company is engaging the FDA for permission to use RadioGel™ for the treatment of advanced basal and squamous skin cancers. The IsoPet Solutions division is focused on demonstrating the safety and therapeutic effectiveness for different animal cancers in four different university veterinary hospitals. After this demonstration phase the plan is to sell RadioGelTM to the private animal clinics. The Company currently is outsourcing material aspects of manufacturing of its product in the United States and intends to enter into licensing arrangements outside of the United States for the manufacturing and distribution of RadioGel™ in other countries. For more information, please visit our websites: www.isotopeworld.com and www.isopetsolutions.com. RadioGel™ is a hydrogel liquid containing tiny Yttrium-90 phosphate particles which may be injected into a tumor. This hydrogel liquid is maintained at a temperature below body temperature but begins to gel, harden, once it is injected into the body and as the temperature increases up to body temperature, thereby locking the particles in place. The particles emit a very high concentrated and contained beta irradiation to kill the tumor. The beta radiation has a short penetration distance so there is minimal collateral damage outside of the injected area. RadioGel™ also has a short half-life - after 10 days only about 5% of the radiation remains; as opposed to other available options that would 50% after 10 days. This is an outpatient treatment much safer to the personnel treating the patient than competing brands and the patient can go home immediately after with no risk to any family members. This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. You can identify these statements by the use of the words "may," "will," "should," "plans," "expects," "anticipates," "continue," "estimates," "projects," "intends," and similar expressions. Forward-looking statements involve risks and uncertainties that could cause results to differ materially from those projected or anticipated. These risks and uncertainties include, but are not limited to, the Company's ability to successfully execute its expanded business strategy, including by entering into definitive agreements with suppliers, commercial partners and customers; general economic and business conditions, effects of continued geopolitical unrest and regional conflicts, competition, changes in technology and methods of marketing, delays in completing various engineering and manufacturing programs, changes in customer order patterns, changes in product mix, continued success in technical advances and delivering technological innovations, shortages in components, production delays due to performance quality issues with outsourced components, regulatory requirements and the ability to meet them, government agency rules and changes, and various other factors beyond the Company's control.


News Article | July 11, 2017
Site: marketersmedia.com

After five months of effort, the AMI team have finalized an improved manufacturing process for our yttrium phosphate particles. We conducted more than thirty process development runs to achieve the most cost-effective process to reproducibly give us the small particles that we desire. Small particles perfuse further into the tumor and reduce the number of injections required for dose coverage in large tumors. In parallel, we concentrated on reducing the time and cost required for manufacturing and increasing the batch yield. As an example, one production step was reduced from 20 hours to just an hour. Product yield increased from 80% to 99.99%. The process is elegantly simple, but based on fundamental understanding of the underlying chemistry involved. IsoTherapeutics, a key manufacturing and testing contractor, did a very professional job working with our team to explore all of the key manufacturing variables. AMI Interim CEO and President Dr. Mike Korenko stated, "This is a significant improvement over the technology that was originally licensed to AMI from the Pacific Northwest National Laboratory. This new proprietary process is an important part of our intellectual property and will reduce our manufacturing costs to position AMI to make a profit on future sales. The manufacturing process has now been institutionalized in a formal Standard Operating Procedure, which is needed to ensure a safe reproducible product for animal and human therapy and it is the protocol required by the Food and Drug Administration." Dr. Korenko added, "This accomplishment required a great deal of effort and is a major step in executing our business plan, which I outlined in my first letter to Shareholders January 2017." AMI previously created the Standard Operating Procedures for the hydrogel (RadioGel™). We are now working on the Quality Assurance and Quality Control Plans and to convert all process activities to GMP (Good Manufacturing Processes) which is a FDA requirement. This will complete the entire disciplined manufacturing process requirements. The strategic market sector of Advanced Medical Isotope Corporation (ADMD) is isotope applications. Currently, the company is engaged in the development of RadioGelTM, an Yttrium-90 based brachytherapy device, for the treatment of tumors. Brachytherapy uses radiation to destroy cancerous tumors by placing a radioactive isotope inside the treatment area. The company is engaging the FDA for permission to use RadioGel for the treatment of advanced basal and squamous skin cancers. The IsoPet Solutions division is focused on demonstrating the safety and therapeutic effectiveness for different animal cancers in four different university veterinary hospitals. After this demonstration phase the plan is to sell RadioGelTM to the private animal clinics. The Company currently is outsourcing material aspects of manufacturing of its product in the United States and intends to enter into licensing arrangements outside of the United States for the manufacturing and distribution of RadioGelTM in other countries. For more information, please visit our websites: www.isotopeworld.com and www.isopetsolutions.com. RadioGel™ is a hydrogel liquid containing tiny Yttrium-90 phosphate particles which may be injected into a tumor. This hydrogel liquid is maintained at a temperature below body temperature but begins to gel, harden, once it is injected into the body and as the temperature increases up to body temperature, thereby locking the particles in place. The particles emit a very high concentrated and contained beta irradiation to kill the tumor. The beta radiation has a short penetration distance so there is minimal collateral damage outside of the injected area. RadioGel™ also has a short half-life - after 10 days only about 5% of the radiation remains; as opposed to other available options that would 50% after 10 days. This is an outpatient treatment much safer to the personnel treating the patient than competing brands and the patient can go home immediately after with no risk to any family members. This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. You can identify these statements by the use of the words "may," "will," "should," "plans," "expects," "anticipates," "continue," "estimates," "projects," "intends," and similar expressions. Forward-looking statements involve risks and uncertainties that could cause results to differ materially from those projected or anticipated. These risks and uncertainties include, but are not limited to, the Company's ability to successfully execute its expanded business strategy, including by entering into definitive agreements with suppliers, commercial partners and customers; general economic and business conditions, effects of continued geopolitical unrest and regional conflicts, competition, changes in technology and methods of marketing, delays in completing various engineering and manufacturing programs, changes in customer order patterns, changes in product mix, continued success in technical advances and delivering technological innovations, shortages in components, production delays due to performance quality issues with outsourced components, regulatory requirements and the ability to meet them, government agency rules and changes, and various other factors beyond the Company's control.


RICHLAND, Wash., Sept. 14, 2017 (GLOBE NEWSWIRE) -- Advanced Medical Isotope Corporation ("AMI") (OTC PINK:ADMD), a late stage radiation oncology focused medical device company’s business plan is to generate initial revenues from animal therapy while pursuing FDA approval to use RadioGel™ for skin cancer in humans. The strategy is to prove the safety and effectiveness of the product via testing at four university veterinary hospitals. Consolidation in the private veterinary clinic space enables the Company to cost-effectively form business arrangements with the large consortiums of private clinics. We met and had discussions with the Veterinary Cancer Group (VCG) and with VCA Inc. to gain firsthand information on the steps required to market RadioGel™ in the commercial sector. VCG has 55 veterinary centers feeding into three specialty clinics. VCA has 820 clinics in the US and Canada feeding into approximately 25 specialty treatment centers. Both consortiums confirmed the importance of learning from the testing that we are sponsoring at the university veterinary centers. They encouraged us to publish the results in a scientific journal. VCG was interested in teaming with the universities by conducting some of the testing in their own facilities. They both emphasized the importance of obtaining a written confirmation from the veterinary side of the FDA that RadioGel™ is a device. After the data collection is completed the results will be sent to their internal review boards for approval. The final stage is a business contract to purchase RadioGel™ for use in their clinics. Cancer is the leading cause of death for 32% of cats and 50% of dogs over age ten. Treating just 10% of pet cancers at an average treatment cost of $5,000 could generate $40 million in annual revenue for the Company. RadioGelTM will provide a more effective therapy that will benefit both the pets and their owners. Getting into the field is the best way to start building the relationships and to determine precisely the steps required for implementation. We requested confirmation from the FDA Center for Veterinary Medicine (CVM) that RadioGelTM is also designated as a device for use in animals since we have been confirmed since 2013 as a device for use in humans. We anticipate completing the majority of the university testing in the 1st quarter of 2018. About Advanced Medical Isotope Corporation (“AMI”) (OTC:ADMD) The strategic market sector of Advanced Medical Isotope Corporation (AMI) is isotope applications.  Currently, the Company is engaged in the development of RadioGel™, an Yttrium-90 based brachytherapy device, for the treatment of tumors. Brachytherapy uses radiation to destroy cancerous tumors by placing a radioactive isotope inside the treatment area. The company is engaging the FDA for permission to use RadioGel™ for the treatment of advanced basal and squamous cell skin cancers. The IsoPet Solutions division of AMI is focused on demonstrating the safety and therapeutic effectiveness for different animal cancers in four different university veterinary hospitals. AMI is positioning itself so that after this demonstration phase, The Company can begin to generate revenues through the sale of RadioGel™ to private animal clinics. The Company currently is outsourcing material aspects of manufacturing of its product in the United States and intends to enter into licensing arrangements outside of the United States for the manufacturing and distribution of RadioGel™ in other countries. RadioGel™ is a hydrogel liquid containing tiny Yttrium-90 phosphate particles to be injected into a tumor.  This hydrogel is a liquid at temperatures below body temperature but begins to gel, harden, upon injection as the temperature increases to normal body temperature, thereby locking the particles in place. The particles emit a very high concentrated and contained beta irradiation to kill the tumor. The beta radiation has a short penetration distance so there is minimal collateral damage to healthy tissues outside of the injected area. RadioGel™ also has a short half-life – delivering more than 90% of its therapeutic radiation within 10 days.  This compares favorably to other available treatment options requiring up to 6 weeks or more to deliver a full course of radiation therapy. This is an outpatient treatment much safer to the personnel treating the patient than competing brands and the patient can go home immediately with no risk to family members. Safe Harbor Statement This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. You can identify these statements by the use of the words "may," "will," "should," "plans," "expects," "anticipates," "continue," "estimates," "projects," "intends," and similar expressions. Forward-looking statements involve risks and uncertainties that could cause results to differ materially from those projected or anticipated. These risks and uncertainties include, but are not limited to, the Company's ability to successfully execute its expanded business strategy, including by entering into definitive agreements with suppliers, commercial partners and customers; general economic and business conditions, effects of continued geopolitical unrest and regional conflicts, competition, changes in technology and methods of marketing, delays in completing various engineering and manufacturing programs, changes in customer order patterns, changes in product mix, continued success in technical advances and delivering technological innovations, shortages in components, production delays due to performance quality issues with outsourced components, regulatory requirements and the ability to meet them, government agency rules and changes, and various other factors beyond the Company's control. For more information, please visit our websites: http://www.isotopeworld.com and www.isopetsolutions.com Direct link to recent presentations and interviews at https://www.redchip.com/company/Biotech/ADMD/376/admd.


News Article | September 26, 2017
Site: www.marketwired.com

RICHLAND, WA--(Marketwired - Sep 26, 2017) - Advanced Medical Isotope Corporation ( : ADMD), a late stage radiation oncology focused medical device company, is pleased to report positive results from the initial study of RadioGel™ at Washington State University (WSU). In the study, researchers at WSU used RadioGel to treat two cats for feline sarcoma. The results indicate RadioGel performed as designed, confirming objective response (destruction of tumor tissue) without any negative or detrimental side-effects. "We are thrilled to see confirmation of RadioGel's potential," stated Dr. Mike Korenko, CEO of ADMD. "The clinical research team at WSU safely achieved near-uniform placement of RadioGel under ultrasound guidance, using the same parallel injection technique that will also be used to treat human skin cancer tumors." Subsequent cat subjects referred to WSU will be treated at higher radiation doses to optimize levels for therapy. The results of the initial study were published in a report, 'A Research Update on RadioGel™ for Treating Feline Sarcomas', which can be viewed on the IsoPet section of ADMD's website https://www.radiogel.com/isopet/animal-studies-updates. Additional status and progress updates of future animal testing will also be made available on this page. It is estimated six million new cancer diagnoses are made in dogs and a similar number made in cats each year (see http://ccr.nci.nih.gov). Treating 0.5% of these cases, at an estimated price of $5,000, would generate approximately $300 million in annual revenue, significantly higher than the Company's previous conservative projection of $40 million. The strategic market sector of ADMD is isotope applications. Currently, the Company is engaged in the development of RadioGel, an Yttrium-90 based brachytherapy device, for the treatment of tumors. Brachytherapy uses radiation to destroy cancerous tumors by placing a radioactive isotope inside the treatment area. The company is engaging the FDA for permission to use RadioGel for the treatment of advanced basal and squamous cell skin cancers. The IsoPet Solutions division of ADMD is focused on demonstrating the safety and therapeutic effectiveness for different animal cancers in four different university veterinary hospitals. ADMD is positioning itself so that after this demonstration phase, The Company can begin to generate revenues through the sale of RadioGel to private animal clinics. The Company currently is outsourcing material aspects of manufacturing of its product in the United States and intends to enter into licensing arrangements outside of the United States for the manufacturing and distribution of RadioGel in other countries. RadioGel™ is a hydrogel liquid containing tiny Yttrium-90 phosphate particles to be injected into a tumor. This hydrogel is a liquid at temperatures below body temperature but begins to gel, harden, upon injection as the temperature increases to normal body temperature, thereby locking the particles in place. The particles emit a very high concentrated and contained beta irradiation to kill the tumor. The beta radiation has a short penetration distance so there is minimal collateral damage to healthy tissues outside of the injected area. RadioGel™ also has a short half-life -- delivering more than 90% of its therapeutic radiation within 10 days. This compares favorably to other available treatment options requiring up to 6 weeks or more to deliver a full course of radiation therapy. This is an outpatient treatment much safer to the personnel treating the patient than competing brands and the patient can go home immediately with no risk to family members. This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. You can identify these statements by the use of the words "may," "will," "should," "plans," "expects," "anticipates," "continue," "estimates," "projects," "intends," and similar expressions. Forward-looking statements involve risks and uncertainties that could cause results to differ materially from those projected or anticipated. These risks and uncertainties include, but are not limited to, the Company's ability to successfully execute its expanded business strategy, including by entering into definitive agreements with suppliers, commercial partners and customers; general economic and business conditions, effects of continued geopolitical unrest and regional conflicts, competition, changes in technology and methods of marketing, delays in completing various engineering and manufacturing programs, changes in customer order patterns, changes in product mix, continued success in technical advances and delivering technological innovations, shortages in components, production delays due to performance quality issues with outsourced components, regulatory requirements and the ability to meet them, government agency rules and changes, and various other factors beyond the Company's control. We have changed our email and website to reflect our focus on RadioGel. Please visit our website: www.radiogel.com and a direct link to recent presentations and interviews at https://www.redchip.com/company/Biotech/ADMD/376/admd.


News Article | September 21, 2017
Site: www.marketwired.com

RICHLAND, WA--(Marketwired - Sep 21, 2017) - Advanced Medical Isotope Corporation ( : ADMD), a late stage radiation oncology focused medical device company strengthened its Medical Advisory Board with the recent addition of Dr. Beau Toskich from Mayo Clinic, who has been informally working with the Company's advisory board for the last six months. "We're pleased Dr. Toskich received the necessary permission from Mayo Clinic to join our advisory board. An enthusiastic and competent doctor, he, like others, sees the potential benefits of RadioGel™ for treating cancer," stated Dr. Michael Korenko, President and CEO of ADMD. "Our advisory board now has more than 135 years of combined experience in key disciplines, which provides us with important guidance as we move forward on development and commercialization plans." Dr. Toskich is a Senior Associate Consultant in Vascular and Interventional Radiology at Mayo Clinic's Florida Campus and Assistant Professor, Vascular and Interventional Radiology, at the University of Florida College of Medicine. He earned his M.D. from Florida State University College of Medicine and completed a fellowship in Vascular and Interventional Radiology at the University of Florida. He is Board Certified in Diagnostic Radiology, Vascular and Interventional Radiology, and a Nuclear Regulatory Commission Authorized User. The strategic market sector of ADMD is isotope applications. Currently, the Company is engaged in the development of RadioGel™, an Yttrium-90 based brachytherapy device, for the treatment of tumors. Brachytherapy uses radiation to destroy cancerous tumors by placing a radioactive isotope inside the treatment area. The company is engaging the FDA for permission to use RadioGel™ for the treatment of advanced basal and squamous cell skin cancers. The IsoPet Solutions division of AMI is focused on demonstrating the safety and therapeutic effectiveness for different animal cancers in four different university veterinary hospitals. AMI is positioning itself so that after this demonstration phase, The Company can begin to generate revenues through the sale of RadioGel™ to private animal clinics. The Company currently is outsourcing material aspects of manufacturing of its product in the United States and intends to enter into licensing arrangements outside of the United States for the manufacturing and distribution of RadioGel™ in other countries. About RadioGel™ RadioGel™ is a hydrogel liquid containing tiny Yttrium-90 phosphate particles to be injected into a tumor. This hydrogel is a liquid at temperatures below body temperature but begins to gel, harden, upon injection as the temperature increases to normal body temperature, thereby locking the particles in place. The particles emit a very high concentrated and contained beta irradiation to kill the tumor. The beta radiation has a short penetration distance so there is minimal collateral damage to healthy tissues outside of the injected area. RadioGel™ also has a short half-life -- delivering more than 90% of its therapeutic radiation within 10 days. This compares favorably to other available treatment options requiring up to 6 weeks or more to deliver a full course of radiation therapy. This is an outpatient treatment much safer to the personnel treating the patient than competing brands and the patient can go home immediately with no risk to family members. This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. You can identify these statements by the use of the words "may," "will," "should," "plans," "expects," "anticipates," "continue," "estimates," "projects," "intends," and similar expressions. Forward-looking statements involve risks and uncertainties that could cause results to differ materially from those projected or anticipated. These risks and uncertainties include, but are not limited to, the Company's ability to successfully execute its expanded business strategy, including by entering into definitive agreements with suppliers, commercial partners and customers; general economic and business conditions, effects of continued geopolitical unrest and regional conflicts, competition, changes in technology and methods of marketing, delays in completing various engineering and manufacturing programs, changes in customer order patterns, changes in product mix, continued success in technical advances and delivering technological innovations, shortages in components, production delays due to performance quality issues with outsourced components, regulatory requirements and the ability to meet them, government agency rules and changes, and various other factors beyond the Company's control. For more information, please visit www.radiogel.com


Basal cell carcinoma and squamous cell carcinoma (skin cancers) selected, representing over 5,500,000 diagnoses annually in the US alone, making it the most prevalent cancer today KENNEWICK, WA / ACCESSWIRE / February 28, 2017 / Advanced Medical Isotope Corporation ("AMI") (OTC PINK: ADMD), a cancer therapeutics company focused on the commercialization of their RadioGel™ device, a tumor-injectable and biodegradable radiation that remains focused at the treatment site, today released the third letter in a four letter series outlining AMI's push towards FDA submittal and commercialization from its new President & CEO, Dr. Mike Korenko. After two months of dynamic experience-based discussions among our Medical Advisory Board Members and other senior doctors we have selected our first indication for use which we will present to the Food and Drug Administration. After thorough review to prioritize indications, we have selected basal cell and squamous cell carcinoma (skin cancers). The reasons for this important selection relates to our criteria below: This cancer is in the skin and therefore easy to access. Single injections for small tumors are easy and we have already demonstrated our parallel injection procedure in the cat at Washington State University for larger tumors. b. Therapeutic ratio (ratio of the dose to the tumor target tissue relative to dose to adjacent normal tissue) and responsiveness to radiation: Yttrium-90 is a beta emitter in RadioGel has a much higher therapeutic ratio than any gamma emitter or external beam therapy. Since Y-90 delivers high-energy beta-rays, it has an average penetration path of 4 to 5 mm (less than a quarter inch), which is ideal for skin cancer therapy. There is minimal irradiation of normal surrounding tissue. As an added bonus, the patient can go home immediately with no irradiation risk to themselves or family members. We can treat with very high doses, so response to radiation would not be an issue. (As a comparison, external beam radiation can deliver 60 to 80 Gy. Yttrium-90 in RadioGel can go to 700 Gy or higher). As discussed above, there is very low risk of collateral damage. In addition, the skin is not located next to a major organ, for example if you were injecting near spinal tumors. Because of the low collateral risk and because of the therapeutic effects that would be relatively easy to see in three months, the Medical Advisory Board felt this might be an easier device for the FDA to approve and in a shorter timeframe. In addition, some of our animal testing, that will start in about two months, are already treating similar cancers. We intentionally avoided applying to the FDA for melanoma, since it is highly metastatic and goes deep into the tissue. There are a much smaller number of cases for this cancer type (around 300,000). In addition, there are three new immunotherapy products on the market to treat melanoma cancer. They can have serious side-effects, but they are promising. That violates our next criterion below. Some skin cancers require several-hour long surgeries in which the tumor is removed, one layer at a time, and then sent for biopsy. They then require a skin graft that can lead to an infection. On tumors of the face this can be disfiguring. As people get older their skin gets thinner, which increases the difficulty. Our Advisory Board felt that for these cases in particular RadioGel has a significant therapeutic advantage. It would benefit the patient and contribute to reducing the cost of health care. 3. CAN BE PROFITABLY EMBRACED BY THE MEDICAL COMMUNITY: One out of every three new cancers in the United States is a cancerous skin lesion. The two skin cancer types that we selected are the most common. There are 3.3 million patients in the United States with 5.5 million tumors (some patients have more than one tumor.) About 1 million of these are squamous cell cancers located near the surface of the epidermal skin layer, and greater than 4 million are basal cell cancers in the deep layer of the epidermis. I would never say that we can treat them all; that would just be marketing hype, but I believe that this will be the preferred treatment in a substantial number of cases in a very large market. b. Ease of acceptance by the medical community, Medicare reimbursement: The potential lower cost of RadioGel therapy coupled with the potential very large number of patients satisfied this criterion. To further test the criterion, we are in discussions with a major private clinic with several skin treatment centers. This client believes this is a great new tool for their toolbox. They are also advising us on the obstacles that will have to be overcome, such as our Medicare reimbursement criterion. Since we believe RadioGel therapy will reduce the cost to Medicare we are confident that will not be an obstacle. There are other cancer types on our list of eighteen potential indications of use for RadioGel, and we have already prioritized to present them to the FDA in the future. Unfortunately, in the meantime, those patients will not be benefiting from this technology. As I have reported in my last shareholder letter, I am aligning the veterinarian animal testing with the human skin cancer. Specially, the University of Missouri will be focusing on the treatment for surface soft cell lesions, and Colorado State University will be refining the therapies for oral squamous cell cancers. After this selection, our next step is to prepare for the FDA pre-submittal meeting. We will request that meeting after we complete the test plans that will answer their previous questions. Until we complete these plans I can only estimate that our pre-submission to the FDA would be in June. I am really happy that we have engaged John Smith from Hogan Lovells to be at our side through this FDA process. I am excited and relieved that this selection decision had been made and I wanted to thank the members of our Medical Advisory Board – Chairman Dr. Barry D. Pressman, Dr. Albert DeNittis, Dr. Howard Sandler, and Dr. Darrell Fisher. I would also like to thank Dr. Ricardo Paz-Fumagalli and Dr. Beau Bosko Toskich from the Mayo Clinic for their valuable advice. In addition to the important developments discussed above, we continue to believe that the public markets are significantly undervaluing our company. With a fully diluted enterprise value of less than $10 million, there remains very large upside potential. As we progress on our plan, I intend to work vigorously to educate and inform the medical and investment community as to the therapeutic benefits our core technology as well as the economic model that can generate significant revenue and profits. We are committed to pursuing an uplisting to a national exchange as soon as possible in order to gain wider exposure and credibility in our pursuit of the multi-billion-dollar addressable market for Radiogel™, that can both significantly improve patient outcomes and reward shareholders. Advanced Medical Isotope Corporation (ADMD) is a late stage radiation oncology focused medical device company engaged in the development of yttrium-90 based brachytherapy devices for cancer treatment. The IsoPet Solutions division is focused on utilizing RadioGel for a cancer therapy in animals. Brachytherapy uses radiation to destroy cancerous tumors by placing a radioactive isotope inside or next to the treatment area. The Company intends to outsource material aspects of manufacturing, distribution, sales and marketing for its products in the United States and to enter into licensing arrangements outside of the United States, though the Company will evaluate its alternatives before finalizing its plans. For more information, please visit our websites: www.isopetsolutions.com and www.isotopeworld.com. This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. You can identify these statements by the use of the words "may," "will," "should," "plans," "expects," "anticipates," "continue," "estimates," "projects," "intends," and similar expressions. Forward-looking statements involve risks and uncertainties that could cause results to differ materially from those projected or anticipated. These risks and uncertainties include, but are not limited to, the Company's ability to successfully execute its expanded business strategy, including by entering into definitive agreements with suppliers, commercial partners and customers; general economic and business conditions, effects of continued geopolitical unrest and regional conflicts, competition, changes in technology and methods of marketing, delays in completing various engineering and manufacturing programs, changes in customer order patterns, changes in product mix, continued success in technical advances and delivering technological innovations, shortages in components, production delays due to performance quality issues with outsourced components, regulatory requirements and the ability to meet them, government agency rules and changes, and various other factors beyond the Company's control.


Basal cell carcinoma and squamous cell carcinoma (skin cancers) selected, representing over 5,500,000 diagnoses annually in the US alone, making it the most prevalent cancer today KENNEWICK, WA / ACCESSWIRE / February 28, 2017 / Advanced Medical Isotope Corporation ("AMI") (OTC PINK: ADMD), a cancer therapeutics company focused on the commercialization of their RadioGel™ device, a tumor-injectable and biodegradable radiation that remains focused at the treatment site, today released the third letter in a four letter series outlining AMI's push towards FDA submittal and commercialization from its new President & CEO, Dr. Mike Korenko. After two months of dynamic experience-based discussions among our Medical Advisory Board Members and other senior doctors we have selected our first indication for use which we will present to the Food and Drug Administration. After thorough review to prioritize indications, we have selected basal cell and squamous cell carcinoma (skin cancers). The reasons for this important selection relates to our criteria below: This cancer is in the skin and therefore easy to access. Single injections for small tumors are easy and we have already demonstrated our parallel injection procedure in the cat at Washington State University for larger tumors. b. Therapeutic ratio (ratio of the dose to the tumor target tissue relative to dose to adjacent normal tissue) and responsiveness to radiation: Yttrium-90 is a beta emitter in RadioGel has a much higher therapeutic ratio than any gamma emitter or external beam therapy. Since Y-90 delivers high-energy beta-rays, it has an average penetration path of 4 to 5 mm (less than a quarter inch), which is ideal for skin cancer therapy. There is minimal irradiation of normal surrounding tissue. As an added bonus, the patent can go home immediately with no irradiation risk to themselves or family members. We can treat with very high doses, so response to radiation would not be an issue. (As a comparison, external beam radiation can deliver 60 to 80 Gy. Yttrium-90 in RadioGel can go to 700 Gy or higher). As discussed above, there is very low risk of collateral damage. In addition, the skin is not located next to a major organ, for example if you were injecting near spinal tumors. Because of the low collateral risk and because of the therapeutic effects that would be relatively easy to see in three months, the Medical Advisory Board felt this might be an easier device for the FDA to approve and in a shorter timeframe. In addition, some of our animal testing, that will start in about two months, are already treating similar cancers. We intentionally avoided applying to the FDA for melanoma, since it is highly metastatic and goes deep into the tissue. There are a much smaller number of cases for this cancer type (around 300,000). In addition, there are three new immunotherapy products on the market to treat melanoma cancer. They can have serious side-effects, but they are promising. That violates our next criterion below. Some skin cancers require several-hour long surgeries in which the tumor is removed, one layer at a time, and then sent for biopsy. They then require a skin graft that can lead to an infection. On tumors of the face this can be disfiguring. As people get older their skin gets thinner, which increases the difficulty. Our Advisory Board felt that for these cases in particular RadioGel has a significant therapeutic advantage. It would be comparatively benefit the patient and contribute to reducing the cost of health care. 3. CAN BE PROFITABLY EMBRACED BY THE MEDICAL COMMUNITY: One out or every three new cancers in the United States is a cancerous skin lesion. The two skin cancer types that we selected are the most common. There are 3.3 million patients in the United States with 5.5 million tumors (some patients have more than one tumor.) About 1 million of these are squamous cell cancers located near the surface of the epidermal skin layer, and greater than 4 million are basal cell cancers in the deep layer of the epidermis. I would never say that we can treat them all; that would just be marketing hype, but I believe that this will be the preferred treatment in a substantial number of cases in a very large market. b. Ease of acceptance by the medical community, Medicare reimbursement: The potential lower cost of RadioGel therapy coupled with the potential very large number of patients satisfied this criterion. To further test the criterion, we are in discussions with a major private clinic with several skin treatment centers. This client believes this is a great new tool for their toolbox. They are also advising us on the obstacles that will have to be overcome, such our Medicare reimbursement criterion. Since we believe RadioGel therapy will reduce the cost to Medicare we are confident that will not be an obstacle. There are other cancer types on our list of eighteen potential indications of use for RadioGel, and we have already prioritized to present them to the FDA in the future. Unfortunately, in the meantime, those patients will not be befitting from this technology. As I have reported in my last shareholder letter, I am aligning the veterinarian animal testing with the human skin cancer. Specially, the University of Missouri will be focusing on the treatment for surface soft cell lesions, and Colorado State University will be refining the therapies for oral squamous cell cancers. After this selection, our next step is to prepare for the FDA pre-submittal meeting. We will request that meeting after we complete the test plans that will answer their previous questions. Until we complete these plans I can only estimate that our pre-submission to the FDA would be in June. I am really happy that we have engaged John Smith from Hogan Lovells to be at our side through this FDA process. I am excited and relieved that this selection decision had been made and I wanted to thank the members of our Medical Advisory Board – Chairman Dr. Barry D. Pressman, Dr. Albert DeNittis, Dr. Howard Sandler, and Dr. Darrell Fisher. I would also like to thank Dr. Ricardo Paz-Fumagalli and Dr. Beau Bosko Toskich from the Mayo Clinic for their valuable advice. In addition to the important developments discussed above, we continue to believe that the public markets are significantly undervaluing our company. With a fully diluted enterprise value of less than $10 million, there remains very large upside potential. As we progress on our plan, I intend to work vigorously to educate and inform the medical and investment community as to the therapeutic benefits our core technology as well as the economic model that can generate significant revenue and profits. We are committed to pursuing an uplisting to a national exchange as soon as possible in order to gain wider exposure and credibility in our pursuit of the multi-billion-dollar addressable market for Radiogel™, that can both significantly improve patient outcomes and reward shareholders. Advanced Medical Isotope Corporation (ADMD) is a late stage radiation oncology focused medical device company engaged in the development of yttrium-90 based brachytherapy devices for cancer treatment. The IsoPet Solutions division is focused on utilizing RadioGel for a cancer therapy in animals. Brachytherapy uses radiation to destroy cancerous tumors by placing a radioactive isotope inside or next to the treatment area. The Company intends to outsource material aspects of manufacturing, distribution, sales and marketing for its products in the United States and to enter into licensing arrangements outside of the United States, though the Company will evaluate its alternatives before finalizing its plans. For more information, please visit our websites: www.isopetsolutions.com and www.isotopeworld.com. This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. You can identify these statements by the use of the words "may," "will," "should," "plans," "expects," "anticipates," "continue," "estimates," "projects," "intends," and similar expressions. Forward-looking statements involve risks and uncertainties that could cause results to differ materially from those projected or anticipated. These risks and uncertainties include, but are not limited to, the Company's ability to successfully execute its expanded business strategy, including by entering into definitive agreements with suppliers, commercial partners and customers; general economic and business conditions, effects of continued geopolitical unrest and regional conflicts, competition, changes in technology and methods of marketing, delays in completing various engineering and manufacturing programs, changes in customer order patterns, changes in product mix, continued success in technical advances and delivering technological innovations, shortages in components, production delays due to performance quality issues with outsourced components, regulatory requirements and the ability to meet them, government agency rules and changes, and various other factors beyond the Company's control. Basal cell carcinoma and squamous cell carcinoma (skin cancers) selected, representing over 5,500,000 diagnoses annually in the US alone, making it the most prevalent cancer today KENNEWICK, WA / ACCESSWIRE / February 28, 2017 / Advanced Medical Isotope Corporation ("AMI") (OTC PINK: ADMD), a cancer therapeutics company focused on the commercialization of their RadioGel™ device, a tumor-injectable and biodegradable radiation that remains focused at the treatment site, today released the third letter in a four letter series outlining AMI's push towards FDA submittal and commercialization from its new President & CEO, Dr. Mike Korenko. After two months of dynamic experience-based discussions among our Medical Advisory Board Members and other senior doctors we have selected our first indication for use which we will present to the Food and Drug Administration. After thorough review to prioritize indications, we have selected basal cell and squamous cell carcinoma (skin cancers). The reasons for this important selection relates to our criteria below: This cancer is in the skin and therefore easy to access. Single injections for small tumors are easy and we have already demonstrated our parallel injection procedure in the cat at Washington State University for larger tumors. b. Therapeutic ratio (ratio of the dose to the tumor target tissue relative to dose to adjacent normal tissue) and responsiveness to radiation: Yttrium-90 is a beta emitter in RadioGel has a much higher therapeutic ratio than any gamma emitter or external beam therapy. Since Y-90 delivers high-energy beta-rays, it has an average penetration path of 4 to 5 mm (less than a quarter inch), which is ideal for skin cancer therapy. There is minimal irradiation of normal surrounding tissue. As an added bonus, the patent can go home immediately with no irradiation risk to themselves or family members. We can treat with very high doses, so response to radiation would not be an issue. (As a comparison, external beam radiation can deliver 60 to 80 Gy. Yttrium-90 in RadioGel can go to 700 Gy or higher). As discussed above, there is very low risk of collateral damage. In addition, the skin is not located next to a major organ, for example if you were injecting near spinal tumors. Because of the low collateral risk and because of the therapeutic effects that would be relatively easy to see in three months, the Medical Advisory Board felt this might be an easier device for the FDA to approve and in a shorter timeframe. In addition, some of our animal testing, that will start in about two months, are already treating similar cancers. We intentionally avoided applying to the FDA for melanoma, since it is highly metastatic and goes deep into the tissue. There are a much smaller number of cases for this cancer type (around 300,000). In addition, there are three new immunotherapy products on the market to treat melanoma cancer. They can have serious side-effects, but they are promising. That violates our next criterion below. Some skin cancers require several-hour long surgeries in which the tumor is removed, one layer at a time, and then sent for biopsy. They then require a skin graft that can lead to an infection. On tumors of the face this can be disfiguring. As people get older their skin gets thinner, which increases the difficulty. Our Advisory Board felt that for these cases in particular RadioGel has a significant therapeutic advantage. It would be comparatively benefit the patient and contribute to reducing the cost of health care. 3. CAN BE PROFITABLY EMBRACED BY THE MEDICAL COMMUNITY: One out or every three new cancers in the United States is a cancerous skin lesion. The two skin cancer types that we selected are the most common. There are 3.3 million patients in the United States with 5.5 million tumors (some patients have more than one tumor.) About 1 million of these are squamous cell cancers located near the surface of the epidermal skin layer, and greater than 4 million are basal cell cancers in the deep layer of the epidermis. I would never say that we can treat them all; that would just be marketing hype, but I believe that this will be the preferred treatment in a substantial number of cases in a very large market. b. Ease of acceptance by the medical community, Medicare reimbursement: The potential lower cost of RadioGel therapy coupled with the potential very large number of patients satisfied this criterion. To further test the criterion, we are in discussions with a major private clinic with several skin treatment centers. This client believes this is a great new tool for their toolbox. They are also advising us on the obstacles that will have to be overcome, such our Medicare reimbursement criterion. Since we believe RadioGel therapy will reduce the cost to Medicare we are confident that will not be an obstacle. There are other cancer types on our list of eighteen potential indications of use for RadioGel, and we have already prioritized to present them to the FDA in the future. Unfortunately, in the meantime, those patients will not be befitting from this technology. As I have reported in my last shareholder letter, I am aligning the veterinarian animal testing with the human skin cancer. Specially, the University of Missouri will be focusing on the treatment for surface soft cell lesions, and Colorado State University will be refining the therapies for oral squamous cell cancers. After this selection, our next step is to prepare for the FDA pre-submittal meeting. We will request that meeting after we complete the test plans that will answer their previous questions. Until we complete these plans I can only estimate that our pre-submission to the FDA would be in June. I am really happy that we have engaged John Smith from Hogan Lovells to be at our side through this FDA process. I am excited and relieved that this selection decision had been made and I wanted to thank the members of our Medical Advisory Board – Chairman Dr. Barry D. Pressman, Dr. Albert DeNittis, Dr. Howard Sandler, and Dr. Darrell Fisher. I would also like to thank Dr. Ricardo Paz-Fumagalli and Dr. Beau Bosko Toskich from the Mayo Clinic for their valuable advice. In addition to the important developments discussed above, we continue to believe that the public markets are significantly undervaluing our company. With a fully diluted enterprise value of less than $10 million, there remains very large upside potential. As we progress on our plan, I intend to work vigorously to educate and inform the medical and investment community as to the therapeutic benefits our core technology as well as the economic model that can generate significant revenue and profits. We are committed to pursuing an uplisting to a national exchange as soon as possible in order to gain wider exposure and credibility in our pursuit of the multi-billion-dollar addressable market for Radiogel™, that can both significantly improve patient outcomes and reward shareholders. Advanced Medical Isotope Corporation (ADMD) is a late stage radiation oncology focused medical device company engaged in the development of yttrium-90 based brachytherapy devices for cancer treatment. The IsoPet Solutions division is focused on utilizing RadioGel for a cancer therapy in animals. Brachytherapy uses radiation to destroy cancerous tumors by placing a radioactive isotope inside or next to the treatment area. The Company intends to outsource material aspects of manufacturing, distribution, sales and marketing for its products in the United States and to enter into licensing arrangements outside of the United States, though the Company will evaluate its alternatives before finalizing its plans. For more information, please visit our websites: www.isopetsolutions.com and www.isotopeworld.com. This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. You can identify these statements by the use of the words "may," "will," "should," "plans," "expects," "anticipates," "continue," "estimates," "projects," "intends," and similar expressions. Forward-looking statements involve risks and uncertainties that could cause results to differ materially from those projected or anticipated. These risks and uncertainties include, but are not limited to, the Company's ability to successfully execute its expanded business strategy, including by entering into definitive agreements with suppliers, commercial partners and customers; general economic and business conditions, effects of continued geopolitical unrest and regional conflicts, competition, changes in technology and methods of marketing, delays in completing various engineering and manufacturing programs, changes in customer order patterns, changes in product mix, continued success in technical advances and delivering technological innovations, shortages in components, production delays due to performance quality issues with outsourced components, regulatory requirements and the ability to meet them, government agency rules and changes, and various other factors beyond the Company's control.


Hires Expert FDA Device Submission Firm; Outlines In-Parallel FDA Data Collection Strategy; Expands Medical Advisory Board with Doctors from 2 Top Cancer Hospitals; Narrows Indication List from 18 to 6 KENNEWICK, WA / ACCESSWIRE / February 14, 2017 / Advanced Medical Isotope Corporation ("AMI") (OTC PINK: ADMD), a cancer therapeutics company focused on the commercialization of their RadioGel™ device, a tumor-injectable and biodegradable radiation that remains focused at the treatment site, today released a letter from its new President and CEO, Dr. Mike Korenko: With my first letter on January 11, I shared AMI's plans for our near-term future. With this letter, I will discuss the progress on that plan in the medical sector of our business over the last month. PATH FORWARD WITH THE FOOD AND DRUG ADMINISTRATION (FDA) In order to maximize our expertise in communicating with the FDA, I spent a lot of time locating the correct FDA expert to be at our side. We have engaged Hogan Lovells. They have 21 lawyers in the field of FDA devices and are very familiar with the personnel at the FDA. We are thrilled to have the input of senior partner John Smith, M.D., J.D. As both a physician and a lawyer, John combines clinical and regulatory experience relating to the FDA with a practical approach to addressing the regulatory issues. He places a particular focus on bringing device-based technologies to market. John and his lawyers have just completed the review of all our previous FDA communications and our supporting data. Based on their recommendations with respect to interacting with the FDA, we intend to: 1. Introduce AMI's new leadership and let them know we have listened; we are narrowing our indication for use to secure our first approval and completing the test plans to answer their previous questions for their review. 2. Present our specific test plans and data in a Pre-Submission meeting to clarify the final application. 4. With the FDA's permission, submit a de novo application for approval (FDA.gov De Novo Application FAQs). The FDA classification of RadioGel™ as a device increases our chances of a timely FDA approval exponentially. The critical path on the overall schedule to approval is, first, to complete laboratory testing concurrent with veterinary animal studies, then into human clinical trials. It is my intent to align the animal treatments in our veterinarian business division to support the animal testing required for the FDA to synergize the two divisions, and potentially create time and cost savings. In this parallel strategy, the company looks to move to first-in-man trials as soon as possible, while aggressively pursuing near-term revenues through the veterinary division, IsoPet, and through licensing. Our Medical Advisory Board has been expanded. Under the Chairmanship of Dr. Barry Pressman (a neuroradiology expert at Cedars-Sinai Medical Center in Los Angeles and Past-President of the American College of Radiology), the Board now includes Dr. Albert Denittis (Chief of Radiation Oncology Lankenau Medical Center), and Dr. Howard Sandlin (Ronald H. Bloom Chair in Cancer Therapeutics, Professor and Chair, Department of Radiation Oncology, Cedars-Sinai Medical Center). Their combined medical experience adds up to over 125 years. We have also been harvesting advice from other doctors, including two from the Mayo Clinic. The focus of the Advisory Boards is to prioritize our indications for use (which cancer types to treat first) in order to present them one at a time, in sequence to the FDA. The Board has selected 18 cancers that are good candidates for treatment with RadioGel™. To me, this large number is a confirmation of our belief that RadioGel has broad potential to treat a variety of tumors. From a business standpoint, it set the stage for incremental growth for many years into the future. In the near-term, we are prioritizing this list down to our top three therapy targets based on specific criteria. 1. Potential for FDA approval and successful therapy: a. Accessibility in the body, ease of application b. Therapeutic effectiveness in response to radiation c. Potential collateral risks from injection d. FDA Testing requirements 3. Business considerations a. Number of patients diagnosed yearly b. Ease of acceptance by the medical community c. Medical Insurance and Medicare reimbursement To paraphrase: 1) It works; 2) Nobody has a better mousetrap; and 3) It has to be profitable to the medical business sector. There have been other great products that made it through the FDA and failed, since the medical community did not see a profitable way to adapt the new technology. The medical community cares about saving lives, but they are in a business. We did not want to be surprised by that reality. As of today, we are down to six near-term candidates. We hope to have our final selection before the end of February. This is an important decision, so we need to get it right. I will send out another shareholder letter when we select our first indication for use. I will also discuss our veterinarian sector's business plan, as well as some updates in a near-term communication to you. I hope this was not too much detail, but I am not a big fan of fluff. Advanced Medical Isotope Corporation (ADMD) is a late stage radiation oncology focused medical device company engaged in the development of yttrium-90 based brachytherapy devices for cancer treatment. The IsoPet Solutions division is focused on utilizing RadioGel for a cancer therapy in animals. Brachytherapy uses radiation to destroy cancerous tumors by placing a radioactive isotope inside or next to the treatment area. The Company intends to outsource material aspects of manufacturing, distribution, sales, and marketing for its products in the United States and to enter into licensing arrangements outside of the United States, though the Company will evaluate its alternatives before finalizing its plans. For more information, please visit our websites: www.isopetsolutions.com and www.isotopeworld.com. This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. You can identify these statements by the use of the words "may," "will," "should," "plans," "expects," "anticipates," "continue," "estimates," "projects," "intends," and similar expressions. Forward-looking statements involve risks and uncertainties that could cause results to differ materially from those projected or anticipated. These risks and uncertainties include, but are not limited to, the Company's ability to successfully execute its expanded business strategy, including by entering into definitive agreements with suppliers, commercial partners, and customers; general economic and business conditions, effects of continued geopolitical unrest and regional conflicts, competition, changes in technology and methods of marketing, delays in completing various engineering and manufacturing programs, changes in customer order patterns, changes in product mix, continued success in technical advances and delivering technological innovations, shortages in components, production delays due to performance quality issues with outsourced components, regulatory requirements and the ability to meet them, government agency rules and changes, and various other factors beyond the Company's control. Hires Expert FDA Device Submission Firm; Outlines In-Parallel FDA Data Collection Strategy; Expands Medical Advisory Board with Doctors from 2 Top Cancer Hospitals; Narrows Indication List from 18 to 6 KENNEWICK, WA / ACCESSWIRE / February 14, 2017 / Advanced Medical Isotope Corporation ("AMI") (OTC PINK: ADMD), a cancer therapeutics company focused on the commercialization of their RadioGel™ device, a tumor-injectable and biodegradable radiation that remains focused at the treatment site, today released a letter from its new President and CEO, Dr. Mike Korenko: With my first letter on January 11, I shared AMI's plans for our near-term future. With this letter, I will discuss the progress on that plan in the medical sector of our business over the last month. PATH FORWARD WITH THE FOOD AND DRUG ADMINISTRATION (FDA) In order to maximize our expertise in communicating with the FDA, I spent a lot of time locating the correct FDA expert to be at our side. We have engaged Hogan Lovells. They have 21 lawyers in the field of FDA devices and are very familiar with the personnel at the FDA. We are thrilled to have the input of senior partner John Smith, M.D., J.D. As both a physician and a lawyer, John combines clinical and regulatory experience relating to the FDA with a practical approach to addressing the regulatory issues. He places a particular focus on bringing device-based technologies to market. John and his lawyers have just completed the review of all our previous FDA communications and our supporting data. Based on their recommendations with respect to interacting with the FDA, we intend to: 1. Introduce AMI's new leadership and let them know we have listened; we are narrowing our indication for use to secure our first approval and completing the test plans to answer their previous questions for their review. 2. Present our specific test plans and data in a Pre-Submission meeting to clarify the final application. 4. With the FDA's permission, submit a de novo application for approval (FDA.gov De Novo Application FAQs). The FDA classification of RadioGel™ as a device increases our chances of a timely FDA approval exponentially. The critical path on the overall schedule to approval is, first, to complete laboratory testing concurrent with veterinary animal studies, then into human clinical trials. It is my intent to align the animal treatments in our veterinarian business division to support the animal testing required for the FDA to synergize the two divisions, and potentially create time and cost savings. In this parallel strategy, the company looks to move to first-in-man trials as soon as possible, while aggressively pursuing near-term revenues through the veterinary division, IsoPet, and through licensing. Our Medical Advisory Board has been expanded. Under the Chairmanship of Dr. Barry Pressman (a neuroradiology expert at Cedars-Sinai Medical Center in Los Angeles and Past-President of the American College of Radiology), the Board now includes Dr. Albert Denittis (Chief of Radiation Oncology Lankenau Medical Center), and Dr. Howard Sandlin (Ronald H. Bloom Chair in Cancer Therapeutics, Professor and Chair, Department of Radiation Oncology, Cedars-Sinai Medical Center). Their combined medical experience adds up to over 125 years. We have also been harvesting advice from other doctors, including two from the Mayo Clinic. The focus of the Advisory Boards is to prioritize our indications for use (which cancer types to treat first) in order to present them one at a time, in sequence to the FDA. The Board has selected 18 cancers that are good candidates for treatment with RadioGel™. To me, this large number is a confirmation of our belief that RadioGel has broad potential to treat a variety of tumors. From a business standpoint, it set the stage for incremental growth for many years into the future. In the near-term, we are prioritizing this list down to our top three therapy targets based on specific criteria. 1. Potential for FDA approval and successful therapy: a. Accessibility in the body, ease of application b. Therapeutic effectiveness in response to radiation c. Potential collateral risks from injection d. FDA Testing requirements 3. Business considerations a. Number of patients diagnosed yearly b. Ease of acceptance by the medical community c. Medical Insurance and Medicare reimbursement To paraphrase: 1) It works; 2) Nobody has a better mousetrap; and 3) It has to be profitable to the medical business sector. There have been other great products that made it through the FDA and failed, since the medical community did not see a profitable way to adapt the new technology. The medical community cares about saving lives, but they are in a business. We did not want to be surprised by that reality. As of today, we are down to six near-term candidates. We hope to have our final selection before the end of February. This is an important decision, so we need to get it right. I will send out another shareholder letter when we select our first indication for use. I will also discuss our veterinarian sector's business plan, as well as some updates in a near-term communication to you. I hope this was not too much detail, but I am not a big fan of fluff. Advanced Medical Isotope Corporation (ADMD) is a late stage radiation oncology focused medical device company engaged in the development of yttrium-90 based brachytherapy devices for cancer treatment. The IsoPet Solutions division is focused on utilizing RadioGel for a cancer therapy in animals. Brachytherapy uses radiation to destroy cancerous tumors by placing a radioactive isotope inside or next to the treatment area. The Company intends to outsource material aspects of manufacturing, distribution, sales, and marketing for its products in the United States and to enter into licensing arrangements outside of the United States, though the Company will evaluate its alternatives before finalizing its plans. For more information, please visit our websites: www.isopetsolutions.com and www.isotopeworld.com. This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. You can identify these statements by the use of the words "may," "will," "should," "plans," "expects," "anticipates," "continue," "estimates," "projects," "intends," and similar expressions. Forward-looking statements involve risks and uncertainties that could cause results to differ materially from those projected or anticipated. These risks and uncertainties include, but are not limited to, the Company's ability to successfully execute its expanded business strategy, including by entering into definitive agreements with suppliers, commercial partners, and customers; general economic and business conditions, effects of continued geopolitical unrest and regional conflicts, competition, changes in technology and methods of marketing, delays in completing various engineering and manufacturing programs, changes in customer order patterns, changes in product mix, continued success in technical advances and delivering technological innovations, shortages in components, production delays due to performance quality issues with outsourced components, regulatory requirements and the ability to meet them, government agency rules and changes, and various other factors beyond the Company's control.

Loading ADVANCED MEDICAL ISOTOPE collaborators
Loading ADVANCED MEDICAL ISOTOPE collaborators